Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127692 | 0.93 | ACHE (0.57) | ACHEAKR1B1HDAC1HDAC6MEN1 | |
| SCHEMBL12868556 | 0.86 | ACHE (0.68) | ACHEAKR1B1HDAC1HDAC6MEN1 | |
| SCHEMBL633048 | 0.80 | ACHE (1.00) | ACHEAKR1B1HDAC1HDAC6MEN1 | |
| SCHEMBL8157824 | 0.79 | NISCH (0.51) | ACHEHDAC1HDAC6SIGMAR1 | |
| SCHEMBL8359258 | 0.78 | ACHE (0.71) | ACHEAKR1B1HDAC1HDAC6SLC6A5 | |
| SCHEMBL11186197 | 0.77 | ACHE (0.74) | ACHEAKR1B1HDAC1HDAC6MEN1 | |
| SCHEMBL1988205 | 0.76 | CHRNA7 (0.60) | GAA | |
| SCHEMBL21996391 | 0.75 | HDAC1 (0.49) | HDAC1HDAC6MEN1KMT2AGAA | |
| SCHEMBL6475336 | 0.75 | ACHE (0.53) | ACHEAKR1B1MEN1KMT2AGAA | |
| SCHEMBL8107160 | 0.75 | ACHE (0.67) | ACHEAKR1B1HDAC1HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101029-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2025-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101029-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR1A | ACHE 2035/4885AKR1B1 2457/4885HDAC1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.